Oral glutathione: why the liposomal form changes everything (and what the trials really show)
· by VEXTA Team
What plain glutathione produced in a controlled trial
Start with the negative result, because it is rarely quoted.
Allen 2011 (Journal of Alternative and Complementary Medicine, DOI 10.1089/acm.2010.0716): a randomised, double-blind, placebo-controlled trial in 40 adults without disease, taking 500 mg of oral glutathione twice daily for four weeks — 1,000 mg per day.
Primary outcomes: urinary F2-isoprostanes and 8-OHdG, two oxidative stress markers standardised to creatinine. Erythrocyte glutathione status — reduced GSH, oxidised GSSG and their ratio — was also measured by liquid chromatography–mass spectrometry.
Result: no significant difference between groups at four weeks, neither in F2-isoprostanes (p = 0.38) nor 8-OHdG (p = 0.27). Glutathione status — total reduced, oxidised and ratio — was likewise unchanged.
This is a properly conducted trial, with a placebo arm, and it is negative.
What the liposomal form produced
Sinha 2018 (European Journal of Clinical Nutrition, DOI 10.1038/ejcn.2017.132) tested glutathione encapsulated in liposomes: a one-month pilot clinical study at two doses (500 and 1,000 mg per day) in 12 healthy adults. Levels were measured in whole blood, erythrocytes, plasma and peripheral blood mononuclear cells at baseline and after 1, 2 and 4 weeks.
Levels rose from the first week, with maximum increases at two weeks:
- +40% in whole blood
- +25% in erythrocytes
- +28% in plasma
- +100% in mononuclear cells
The authors themselves describe these findings as preliminary. Twelve participants in a pilot study: a coherent signal, not a demonstration. Comparing this directly with Allen 2011 is also methodologically uneven — one is a controlled trial, the other a pilot.
Formulation is the real variable
Recent work confirms the question is a pharmaceutical one. Jung 2026 (European Journal of Pharmaceutics and Biopharmaceutics, DOI 10.1016/j.ejpb.2026.115174) opens by noting that systemic availability of glutathione following oral administration remains controversial, then compares an orally dissolving film with a conventional tablet in healthy adults.
Result: plasma glutathione concentrations were higher with the film, with significant differences at 4 and 6 hours and a trend toward greater systemic exposure. Over four weeks, both formulations raised circulating glutathione.
In other words: between two products listing the same milligram figure, what decides the outcome is how the molecule is presented for absorption.
What to take away when choosing
Three reference points:
- Form before dose. Plain glutathione at 1,000 mg failed a controlled trial. The milligram is not the relevant unit.
- The studied doses sit between 500 and 1,000 mg per day, whatever the form.
- The evaluation window is short: increases appear within a week and peak at two weeks in the liposomal study.
And the honest caveat: raising a blood level is not the same as producing a clinical benefit. None of these trials demonstrates a health outcome — they measure availability. That is a necessary step, not a sufficient one.